您当前所在的位置:首页 > 产品中心 > 产品信息
Mianserin_分子结构_CAS_24219-97-4)
点击图片或这里关闭

Mianserin

产品号 DB06148 公司名称 DrugBank
CAS号 24219-97-4 公司网站 http://www.ualberta.ca/
分子式 C18H20N2 电 话 (780) 492-3111
分子量 264.3648 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 4416

产品价格信息

请登录

产品别名

标题
Mianserin
IUPAC标准名
5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
IUPAC传统名
5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
商标名
Norval
Bolvidon
Tolvan
别名
Mianserine [inn-french]
Mianserina [inn-spanish]
Mianserine
Mianseryna [polish]
Mianserinum [inn-latin]

产品登记号

CAS号 24219-97-4
PubChem CID 4184
PubChem SID 46508096

产品性质

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favor of Mirtazapine.
Indication For the treatment of depression.
Pharmacology Mianserin is a tetracyclic antidepressant that has antihistaminic and hypnosedative, but almost no anticholinergic, effect. It is a weak inhibitor of norepinephrine reuptake and strongly stimulates the release of norepinephrine. Interactions with serotonin receptors in the central nervous system have also been found. Its effect is usually noticeable after one to three weeks. Mianserin may cause drowsiness and hematological problems.
Toxicity Oral rat LD50: 780mg/kg
Affected Organisms
Humans and other mammals
Biotransformation Hepatic.
Absorption Absorbed following oral administration.
Half Life 10-17 hours
Protein Binding 90%
References
Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. [Pubmed]
de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. [Pubmed]
Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. [Pubmed]
External Links
Wikipedia

参考文献

  • Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. Pubmed
  • de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. Pubmed
  • Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. Pubmed